Increasing Prevalence and Stable Incidence Rates of Inflammatory Bowel Disease Among First Nations: Population-Based Evidence From a Western Canadian Province.
Crohn disease
Indigenous people
epidemiology
inflammatory bowel disease
population group
ulcerative colitis
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
30 03 2022
30 03 2022
Historique:
received:
31
12
2020
pubmed:
27
5
2021
medline:
5
4
2022
entrez:
26
5
2021
Statut:
ppublish
Résumé
There is limited to no evidence of the prevalence and incidence rates of inflammatory bowel disease (IBD) among Indigenous peoples. In partnership with Indigenous patients and family advocates, we aimed to estimate the prevalence, incidence, and trends over time of IBD among First Nations (FNs) since 1999 in the Western Canadian province of Saskatchewan. We conducted a retrospective population-based study linking provincial administrative health data from the 1999-2000 to 2016-2017 fiscal years. An IBD case definition requiring multiple health care contacts was used. The prevalence and incidence data were modeled using generalized linear models and a negative binomial distribution. Models considered the effect of age groups, sex, diagnosis type (ulcerative colitis [UC], Crohn disease [CD]), and fiscal years to estimate prevalence and incidence rates and trends over time. The prevalence of IBD among FNs increased from 64/100,000 (95% confidence interval [CI], 62-66) in 1999-2000 to 142/100,000 (95% CI, 140-144) people in 2016-2017, with an annual average increase of 4.2% (95% CI, 3.2%-5.2%). Similarly, the prevalence of UC and CD, respectively, increased by 3.4% (95% CI, 2.3%-4.6%) and 4.1% (95% CI, 3.3%-4.9%) per year. In contrast, the incidence rates of IBD, UC, and CD among FNs depicted stable trends over time; no statistically significant changes were observed in the annual change trend tests. The ratio of UC to CD was 1.71. We provided population-based evidence of the increasing prevalence and stable incidence rates of IBD among FNs. Further studies are needed in other regions to continue understanding the patterns of IBD among Indigenous peoples.
Sections du résumé
BACKGROUND
There is limited to no evidence of the prevalence and incidence rates of inflammatory bowel disease (IBD) among Indigenous peoples. In partnership with Indigenous patients and family advocates, we aimed to estimate the prevalence, incidence, and trends over time of IBD among First Nations (FNs) since 1999 in the Western Canadian province of Saskatchewan.
METHODS
We conducted a retrospective population-based study linking provincial administrative health data from the 1999-2000 to 2016-2017 fiscal years. An IBD case definition requiring multiple health care contacts was used. The prevalence and incidence data were modeled using generalized linear models and a negative binomial distribution. Models considered the effect of age groups, sex, diagnosis type (ulcerative colitis [UC], Crohn disease [CD]), and fiscal years to estimate prevalence and incidence rates and trends over time.
RESULTS
The prevalence of IBD among FNs increased from 64/100,000 (95% confidence interval [CI], 62-66) in 1999-2000 to 142/100,000 (95% CI, 140-144) people in 2016-2017, with an annual average increase of 4.2% (95% CI, 3.2%-5.2%). Similarly, the prevalence of UC and CD, respectively, increased by 3.4% (95% CI, 2.3%-4.6%) and 4.1% (95% CI, 3.3%-4.9%) per year. In contrast, the incidence rates of IBD, UC, and CD among FNs depicted stable trends over time; no statistically significant changes were observed in the annual change trend tests. The ratio of UC to CD was 1.71.
CONCLUSIONS
We provided population-based evidence of the increasing prevalence and stable incidence rates of IBD among FNs. Further studies are needed in other regions to continue understanding the patterns of IBD among Indigenous peoples.
Identifiants
pubmed: 34037223
pii: 6284047
doi: 10.1093/ibd/izab096
pmc: PMC8972279
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
514-522Subventions
Organisme : NIMHD NIH HHS
ID : L32 MD007420
Pays : United States
Informations de copyright
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
Gastroenterology. 2011 May;140(6):1785-94
pubmed: 21530745
BMC Gastroenterol. 2014 Aug 09;14:140
pubmed: 25108544
Can J Gastroenterol. 2011 Feb;25(2):73-7
pubmed: 21321677
Am J Epidemiol. 1999 May 15;149(10):916-24
pubmed: 10342800
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56-66
pubmed: 33033392
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Inflamm Bowel Dis. 2020 Mar 4;26(4):581-590
pubmed: 31504519
J Crohns Colitis. 2017 Dec 04;11(12):1471-1479
pubmed: 28981633
J Crohns Colitis. 2020 Oct 5;14(10):1354-1363
pubmed: 32648579
J Can Assoc Gastroenterol. 2020 Aug 21;4(4):186-193
pubmed: 34337319
Can J Gastroenterol. 2012 Nov;26(11):811-7
pubmed: 23166905
J Clin Epidemiol. 2014 Aug;67(8):887-96
pubmed: 24774473
Inflamm Bowel Dis. 2021 Oct 20;27(11):1784-1794
pubmed: 33438721
CMAJ. 2018 Jun 18;190(24):E754-E755
pubmed: 29914917
Inflamm Bowel Dis. 2020 Mar 4;26(4):619-625
pubmed: 31504515
Clin Gastroenterol Hepatol. 2018 Feb;16(2):190-197.e11
pubmed: 28603049
Inflamm Bowel Dis. 2014 Oct;20(10):1761-9
pubmed: 25159453
J Can Assoc Gastroenterol. 2021 Mar 16;4(6):296-305
pubmed: 34877469
Gastroenterol Res Pract. 2014;2014:703890
pubmed: 24799892
Aliment Pharmacol Ther. 2020 Jan;51(2):261-270
pubmed: 31660629
Am J Gastroenterol. 2019 Jan;114(1):107-115
pubmed: 30177785
Am J Gastroenterol. 2006 Jul;101(7):1559-68
pubmed: 16863561
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7
pubmed: 26323879
Am J Gastroenterol. 2017 Sep;112(9):1412-1422
pubmed: 28741616
Gastroenterology. 2017 Feb;152(2):313-321.e2
pubmed: 27793607
Intest Res. 2019 Jan;17(1):54-62
pubmed: 30449079
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S6-S16
pubmed: 31294381
Can J Public Health. 2018 Dec;109(5-6):700-709
pubmed: 29981110
CMAJ. 2012 May 15;184(8):E435-41
pubmed: 22496383
Gastroenterology. 2019 Apr;156(5):1345-1353.e4
pubmed: 30639677
Can J Gastroenterol. 2012 Oct;26(10):711-7
pubmed: 23061064
Am J Epidemiol. 2006 Oct 1;164(7):615-23; discussion 624-8
pubmed: 16920784
Inflamm Bowel Dis. 2019 Sep 18;25(10):1718-1728
pubmed: 31211836
Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
pubmed: 22001864
Am J Epidemiol. 2001 Aug 15;154(4):328-35
pubmed: 11495856
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971